Drugs / JCXH-213
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07622329 | Jun → Aug 2026 overdue | autoimmune thrombocytopenic purpura | The General Hospital of Western Theater Command | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06618313 | Mar 2025 → Aug 2026 overdue | B-cell non-Hodgkin lymphoma | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-29 | Immorna Biotherapeutics, Inc. | Results 嘉晨西海宣布in vivo CAR-T疗法JCXH-213在免疫性血小板减少性紫癜患者中取得亮眼临床进展，验证平台治疗自身免疫性疾病潜力 immorna.com ↗
两例经历一、二线治疗失败的顽固复发性 ITP 患者在接受 JCXH-213 初始低剂量治疗后，快速实现了外周血和深层骨髓组织内彻底的 B 细胞清除，血小板计数出现显著且稳步上升，初次用药后仅第八天两例病人均实现完全响应（ Complete Response ），临床获益显著。 |
| 2026-04-14 | Immorna Biotherapeutics, Inc. | Results 嘉晨西海宣布in vivo CAR-T疗法JCXH-213在系统性硬化症患者中实现组织B细胞清除的首项证据，彰显平台治疗自身免疫性疾病潜力 immorna.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-29 | Immorna Biotherapeutics, Inc. | 嘉晨西海宣布in vivo CAR-T疗法JCXH-213在免疫性血小板减少性紫癜患者中取得亮眼临床进展，验证平台治疗自身免疫性疾病潜力 immorna.com ↗ |
| 2026-04-14 | Immorna Biotherapeutics, Inc. | 嘉晨西海宣布in vivo CAR-T疗法JCXH-213在系统性硬化症患者中实现组织B细胞清除的首项证据，彰显平台治疗自身免疫性疾病潜力 immorna.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JCXH-213 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06618313 ↗ |
| Modality | Messenger RNA (mRNA) | “An mRNA-LNP based in vivo CAR therapy” NCT07622329 ↗ |
| Route | Other | “JCXH-213 infusion” NCT06618313 ↗ |